This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Sep;14(9):1383-1384.

doi: 10.1513/AnnalsATS.201706-423ED.

Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis

Brett Ley¹

Affiliations

PMID: 28862501
DOI: 10.1513/AnnalsATS.201706-423ED

Editorial

Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis

Brett Ley. Ann Am Thorac Soc. 2017 Sep.

. 2017 Sep;14(9):1383-1384.

doi: 10.1513/AnnalsATS.201706-423ED.

Author

Brett Ley¹

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.

PMID: 28862501
DOI: 10.1513/AnnalsATS.201706-423ED

No abstract available

PubMed Disclaimer

Comment on

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA, Chowdhury BA. Paterniti MO, et al. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. Ann Am Thorac Soc. 2017. PMID: 28388260

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations